Gilead’s Goldfinch deal signals renewed optimism in kidney therapies

In the latest sign of that the kidney is regaining attention for drug developers, Gilead has tapped Goldfinch's drug discovery tools to co-develop therapies for diabetic kidney disease and orphan kidney diseases.

Goldfinch Biopharma Inc. (Cambridge, Mass.) CEO Tony Johnson told BioCentury that after a string of past failures among pharma companies developing kidney therapies, the space is now opening up with a better regulatory environment and greater understanding of kidney disease. ...